摘要
目的探讨细胞免疫治疗对中晚期胃癌患者免疫状态的影响及其影响因素。方法收集我院消化内科2013年1月至2017年12月72例中晚期胃癌住院患者的病历资料,所有患者治疗措施均为先行单纯化学治疗随后接受DC-CIK细胞免疫治疗,用流式细胞仪检测外周血CD3^+T细胞、CD4^+T细胞、CD8^+T细胞以及NK细胞亚群的百分比水平,观察并比较2阶段治疗前后患者细胞免疫功能指标的变化,进一步应用统计学分析方法得到影响免疫状态的因素。结果 72例中晚期胃癌患者经单纯化学治疗后,外周血CD3^+T细胞、CD4^+T细胞、CD8^+T细胞、NK细胞及CD4^+/CD8^+比值水平均无显著变化;经DC-CIK细胞免疫治疗后,外周血CD3^+T细胞、CD4^+T细胞、CD8^+T细胞、CD4^+/CD8^+比值以及NK细胞亚群水平均有显著变化;不同性别、有无幽门螺旋杆菌感染和不同肿瘤分化程度中晚期胃癌患者细胞免疫治疗后的免疫状态无差异(P>0.05)。不同年龄(P=0.041)、不同肿瘤大小(P=0.025)、不同TNM分期(P=0.017)中晚期胃癌患者细胞免疫治疗后的免疫状态有差异,并且是影响其免疫状态的危险因素。结论 DC-CIK细胞免疫治疗可以改善中晚期胃癌患者免疫状态。TNM分期、年龄和肿瘤大小是DC-CIK治疗中晚期胃癌患者后的免疫状态的危险因素。
This study was performed to investigate the immune function variation after cell immune therapy in patients with medium or advanced gastric cancer and the influence factors.Seventy-two patients with medium or advanced gastric cancer were recruited from chongqing cancer hospital,and were received chemotherapy firstly and then DC-CIK cell immune therapy.Peripheral blood samples were collected before and after chemotherapy and DC-CIK cell immune therapy to detect the percentage of NK cell and T-lymphocyte subsets by flow cytometry.We analyzed and compared the changes of NK cell and T-lymphocyte subtypes and further applied statistical analysis to the factors that influence the immune status of patients with medium and advanced gastric cancer after cell immune therapy.Data showed that there was no significant change in the levels of CD3^+ T cells,CD4^+ T cells,CD8^+ T cells, NK cells,and CD4^+/CD8^+ ratio of 72 patients with medium or advanced chemotherapy,but theses indexes were significantly changed after DC-CIK cell gastric cancer before and after immune therapy.TNM stage (P=0.017),age (P=0.041) and tumor size (P=0.025) were closely related to the immune status of patients with medium or advanced gastric cancer,and they are risk factors influencing the immune status of patients after cell immune therapy.In conclusion,DC-CIK cell immune therapy can improve the immune status of patients with medium or advanced gastric cancer.TNM stage,age and tumor size are risk factors that influence the immune status of patients with medium or advanced gastric cancer after cell immune therapy.
作者
陈诚
王玲
唐家喜
CHEN Cheng;WANG Ling;TANG Jiaxi(Key Labortary for Biorheological Science and Technology of Ministry of Education (Chongqing University),Chongqing University Cancer Hospital &Chongqing Cancer Institute &Chongqing Cancer Hospital,Chongqing 400044,China)
出处
《免疫学杂志》
CAS
CSCD
北大核心
2018年第12期1077-1081,1104,共6页
Immunological Journal
关键词
细胞免疫治疗
化学治疗
中晚期胃癌
影响因素
Cell immune therapy
Chemotherapy
Medium and advanced gastric cancer
Influencing factor
作者简介
通信作者:陈诚,E-mail:361194887@qq.com.
